We monitor you regularly to ensure proper dosing and safety
Avoid grazing or mindless snacking, as this can undermine the appetite-suppressing effects of tirzepatide
Pre-mixed option: Ipamorelin + MOD GRF Blend (3/3 mg)
A review of head-to-head clinical trials comparing key outcomes of using GLP-1RAs (dulaglutide, exenatide BD, exenatide QW, liraglutide or lixisenatide) with those of using DPP-IV (sitagliptin), SU (glimepiride
For carriers of the MC1R rs1805007 effect allele, these habits tend to produce a more noticeable return because they directly influence the signaling environments where the variant has its greatest impact
The New England Journal of Medicine commentary accompanying SURPASS-2 stated: "The dual incretin approach appears to exploit receptor crosstalk in ways that amplify downstream insulin secretion beyond what GLP-1 receptor agonism alone can achieve at comparable tolerability." [30] SURPASS-1: Monotherapy Benchmark SURPASS-1 (N=478) established monotherapy efficacy, with tirzepatide 15 mg reducing A1C by 2.07 percentage points and body weight by 9.5 kg at 40 weeks versus placebo [31]
